HIV-1 integrase inhibitor
CAS: 544467-07-4
Ref. 3D-FA64909
| 25mg | 136.00 € | ||
| 50mg | 201.00 € | ||
| 100mg | 309.00 € | ||
| 250mg | 517.00 € | ||
| 500mg | 803.00 € |
Product Information
- 4-[3-(Azidomethyl)phenyl]-2-hydroxy-4-oxo-2-butenoic acid
Integrase inhibitors are a class of drugs that inhibit the function of integrase. They prevent HIV-1 from integrating into the host cell genome and thus arrest the progression of HIV-1 infection. There are many analytical methods that can be used to determine the presence of integrase in cells, such as transfection experiments, toxicity studies, drug interactions, and bioassays. One pharmacological agent that has been shown to inhibit integrase is raltegravir (Isentress), which is a protease inhibitor. Raltegravir is available in tablet form for oral administration. It inhibits HIV-1 replication by binding to the active site of human immunodeficiency virus type 1 (HIV-1) integrase and prevents its integration into host cell DNA. This drug has been shown to be beneficial when used in conjunction with other antiretroviral agents for treating HIV-1 infections.
Chemical properties
Technical inquiry about: 3D-FA64909 HIV-1 integrase inhibitor
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
